HIV-1 Envelope V2 Loop Optimization for Broad bnAb Induction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HIV-1 vaccines fail to induce high levels of broadly neutralizing antibodies (bnAbs), which are crucial for effective protection against HIV-1 infection, particularly in developing countries where antiretroviral treatment is not readily available.
Innovation Solution
Development of immunogenic compositions comprising optimized V2 loop and CD4 binding site HIV-1 envelope proteins, along with nucleic acids, to induce cross-reactive neutralizing antibodies, using recombinant HIV-1 envelope polypeptides optimized for V2 apex bnAb precursor targeting, and self-assembling proteins like ferritin, administered with adjuvants and carriers to enhance immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current HIV-1 vaccines are administered, then immune response is induced, but broadly neutralizing antibodies are not induced at high levels
Solution Approach 1:
The patent applies local quality by optimizing specific regions of the envelope protein (V2 loop, CD4 binding site, fusion peptide) while maintaining other regions unchanged. This targeted optimization of local epitopes enhances bnAb induction without requiring complete redesign of the entire envelope structure, thereby improving reliability of bnAb induction while managing production complexity.
Solution Approach 2:
The patent employs parameter changes by introducing specific amino acid mutations at defined positions (11 mutations for V2 apex targeting, 5 additional mutations for UCA targeting) to optimize envelope protein conformation and epitope presentation. These parameter changes in the protein sequence directly improve the induction of broadly neutralizing antibodies while maintaining structural integrity for production.
2Adaptability or versatility
If envelope proteins are optimized for specific epitope targeting, then cross-reactive neutralizing antibodies are induced, but protein structure complexity increases
Solution Approach 1:
The patent segments the envelope protein optimization into distinct modular regions: V2 loop optimization (11 mutations), CD4 binding site optimization, and fusion peptide optimization (5 additional mutations). This segmentation allows independent design and optimization of each epitope region, enhancing cross-reactive antibody induction while managing structural complexity through modular construction.
Solution Approach 2:
The patent applies preliminary action by pre-optimizing the envelope protein sequence with specific mutations before immunization to predictably elicit desired antibody responses. The optimized sequences are designed in advance to present specific conformational epitopes, ensuring cross-reactive neutralizing antibody induction without requiring complex post-immunization modifications.
3Reliability
If recombinant envelope polypeptides are used as immunogens, then immune response is enhanced, but manufacturing complexity increases
Solution Approach 1:
The patent uses recombinant DNA technology to create copies of the optimized envelope protein sequence in expression systems. The nucleic acid sequences encoding the optimized envelope proteins are inserted into expression vectors, which are then transformed into host cells for protein production. This copying approach enables scalable manufacturing of the complex optimized immunogens while maintaining consistent structure and function.
Solution Approach 2:
The patent replaces complex chemical synthesis or purification methods with recombinant expression systems. Instead of manually assembling or chemically synthesizing the optimized envelope proteins, the patent uses biological expression systems (cells with inserted expression vectors) to automatically produce the proteins through natural transcription and translation, simplifying manufacturing while enhancing immune response effectiveness.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compositions effectively induce cross-reactive neutralizing antibodies, providing broad coverage and potentially enhancing immune response against HIV-1, laying the groundwork for a more effective HIV-1 vaccine.
Implementation Method 1
the envelope sequence comprises a self-assembling protein, for example but not limited to ferritin
Data Source
AI summary
In certain aspects the invention provides HIV-1 immunogens, including HIV-1 envelopes with optimized V2 loop for antibody induction.